PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of PolyPid Ltd. (NASDAQ:PYPD) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $12.25.

Several analysts have recently weighed in on PYPD shares. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of PolyPid in a research note on Wednesday, February 11th. Finally, Weiss Ratings downgraded PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st.

PolyPid Stock Performance

Shares of PYPD opened at $4.50 on Tuesday. The stock has a market capitalization of $85.86 million, a P/E ratio of -2.36 and a beta of 1.42. The company’s fifty day moving average is $4.56 and its two-hundred day moving average is $4.35. PolyPid has a 1 year low of $2.77 and a 1 year high of $5.21.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. Sell-side analysts predict that PolyPid will post -1.34 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC boosted its position in shares of PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after buying an additional 277,844 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of PolyPid during the 1st quarter worth approximately $81,000. BNP Paribas Financial Markets raised its position in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of PolyPid during the 4th quarter worth approximately $66,000. Finally, XTX Topco Ltd raised its position in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the last quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.